Article

Verteporfin for injection

The FDA has approved Visudyne (verteporfinfor injection) therapy for the treatment of predominantly classic subfovealchoroidal neovascularization (CNV) caused by pathologic myopia and presumedocular histoplasmosis.

Related Videos
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
Related Content
EMA validates indication extension application of pegcetacoplan for treatment of kidney disease
February 23rd 2025

EMA validates indication extension application of pegcetacoplan for treatment of kidney disease

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Hyperacute outer retinal dysfunction may be an underrecognized pediatric disorder
February 22nd 2025

Hyperacute outer retinal dysfunction may be an underrecognized pediatric disorder

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks
February 21st 2025

Heart Eye announces AI-driven retinal imaging system to detect biomarkers of cardiovascular health risks

An illustration of an eye with a DNA helix in the pupil. Image credit: ©artacet – stock.adobe.com
February 20th 2025

Efficacy and safety findings for lenadogene nolparvovec (Lumevoq) from REFLECT Phase III trial

© 2025 MJH Life Sciences

All rights reserved.